Diagnos Inc., a Canadian corporation trading on the TSX Venture Exchange under the symbol ADK, has announced a strategic engagement with Investor Brand Network for corporate communication and awareness services. The agreement, effective January 10, 2026, involves IBN receiving monthly compensation of US$6,400, payable in advance from the corporation's funds. This engagement is designed to refine and strengthen Diagnos's market awareness profile with the primary objective of maximizing shareholder value. The arrangement remains subject to acceptance by the TSX Venture Exchange.
The importance of this announcement lies in its potential impact on investor relations and market perception for a company operating at the intersection of healthcare and technology. Diagnos is a pioneer in using Artificial Intelligence-based technology for the early detection of critical eye-related health problems. By leveraging AI, the company aims to provide healthcare clinicians with enhanced diagnostic tools to improve accuracy, streamline workflows, and ultimately achieve better patient outcomes on a global scale. Additional information about the company's mission and operations is available at https://www.diagnos.com and through regulatory filings at https://www.sedarplus.com.
For investors, the engagement with IBN represents a calculated effort to increase visibility within the investment community. IBN, part of a larger network of over 75 brands, offers a specialized communications platform that includes advanced wire-grade press release syndication, article syndication to thousands of outlets, enhanced press release services, and social media distribution to millions of followers. This comprehensive suite of services, detailed at https://www.InvestorWire.com, is intended to cut through market information overload and provide Diagnos with greater recognition and brand awareness. The latest news and updates relating to the company's OTCQB listing (DGNOF) are available in its dedicated newsroom at https://ibn.fm/DGNOF.
The implications of this corporate communications strategy are significant for both the company and its stakeholders. In a competitive market, effective communication can be crucial for attracting investment, building partnerships, and educating the public about innovative medical technologies. For the healthcare industry, increased awareness of Diagnos's AI-driven diagnostic solutions could accelerate adoption, potentially leading to earlier interventions for patients with eye health issues. The financial commitment, structured as a one-year agreement with specified monthly payments, indicates a sustained, strategic approach to corporate outreach rather than a one-time promotional effort.
This development underscores the growing importance of strategic communications for publicly traded technology and healthcare companies seeking to articulate their value proposition and growth potential to a broad audience of investors, journalists, and industry influencers.
